PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. - sprookjes - yvandenbroek - TriplyDB

PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.

PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.

http://www.wikidata.org/entity/Q35540013

about

Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.Translational and clinical implications of the genetic landscape of prostate cancer.Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.Biomarkers for prostate cancer: present challenges and future opportunities.Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies.Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications.Molecular biomarkers to guide precision medicine in localized prostate cancer.Ductal adenocarcinoma of the prostate: Clinical and biological profiles.DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.Progress in the mechanism and drug development of castration-resistant prostate cancer.Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.The role of PTEN as a cancer biomarker.The molecular underpinnings of prostate cancer: impacts on management and pathology practice.New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer.Genomic tests to guide prostate cancer management following diagnosis.Tumour heterogeneity poses a significant challenge to cancer biomarker research.PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort.Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular Features.Association of PTEN expression with biochemical recurrence in prostate cancer: results based on previous reports.Tissue-based biomarkers in prostate cancer.Precision Medicine and Men's Health.Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer.p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.Downregulation of STRAP promotes tumor growth and metastasis in hepatocellular carcinoma via reducing PTEN level.Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.Is it time for everolimus-based combination in castration-resistant prostate cancer?SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).Current treatment strategies for advanced prostate cancer.PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer.Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer.A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases.Pathology and molecular updates in tumors of the prostate: towards a personalized approach.Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.

P2860

Q26752510-8DCEB5AC-162B-43B5-AB96-DB13A9EE0F61 Q26774456-D8CDE75E-9180-4B68-B39A-CCAA3E9D2A88 Q27853235-78554E17-6E44-494E-BC57-A3AA2A15E1A7 Q35879087-9D1668C0-3953-4396-9891-08C8D55C8C5C Q36275673-A1E940D7-25B0-4E9A-95EF-05F6ADA7CF07 Q36287422-19B5D415-1C27-49B2-A5B6-5234574AB85A Q36407003-67A8AEDE-88EE-40B2-823E-DF72F4787CD1 Q37270512-EDD9A70B-EB1F-4F73-84DB-47E994DCEE72 Q37462283-2BD99C9B-EC4C-43A8-BE9E-BD4731E85D06 Q37474443-31F29B5D-99D2-4A8B-A5DF-17B8EF237540 Q38487988-A53AB06F-15B5-436D-A8C5-016DEBDCAB0B Q38644658-88F48737-3645-464D-A300-D438B5D7FAF0 Q38668635-7AE3E140-ADE8-40B7-BF2B-9D938E6429B3 Q38683009-6106DE29-E9E1-4F18-B5F1-DE8071203C1D Q38774228-0B741222-241C-435D-BC04-361E9175E6FF Q38826609-52F4E304-9170-44CD-8F6E-D54FFFB16678 Q38833458-17F09245-17BE-41F3-8864-257B9AEBEFFF Q38964595-29AD361F-52E1-4E48-89C6-FFD6A4E30BDC Q38983790-57B3CFA4-38EB-48DA-9988-1AD97A5528EE Q38994718-17EE1A3E-5F0A-462B-8A49-B34667D61F2A Q39170943-15F12E95-DBB0-486C-92C8-3CD868290062 Q41193147-6236D60C-8A74-4F53-9199-12584DF29A98 Q42371556-36557721-3EF3-44D5-A877-9C4C0EA7FAE8 Q42690512-8E8685BC-8D37-4468-AB9A-4A852AC78B16 Q47094262-8DBC85C0-E45A-40E0-B460-A777A259D137 Q47144748-FCB92451-7B9A-45BA-8B33-BFE6B1289318 Q47151829-3F8999BE-173C-4AB3-9875-2D7524006B44 Q47215343-9D71AB18-EDD9-4394-91DA-02C70DAC5E4C Q47231171-5EDC7EDF-1C1F-49AC-8202-E958B4AA460B Q47249769-E5467B16-245C-49EB-9031-27B7BC577E74 Q47562402-BEBCDB88-ABC8-4856-B91A-9DFD26F42B1B Q48091118-53B6D48A-B604-4A86-809C-C60ED34EBDC5 Q48310246-CF21BC21-D469-473B-A33A-B15E4B5541B6 Q48561494-CFBFCE89-D7DE-4426-B715-F355A04D5316 Q49788391-20571945-B5EE-49A5-876F-8CC9F72EC999 Q51465026-1FB086C5-BE9D-4112-9D45-66D04052E382 Q51586225-584A1195-192D-4FD2-AB6E-9CDC49601129 Q52318912-B862A06E-E648-4C7D-B6B1-6363EC05AA36 Q52861100-E27EEF4D-A536-4559-A324-22827421C25A Q53045863-9D1885A8-7D41-4648-8E1C-460B5AC0F48E

P2860

PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.

http://www.wikidata.org/entity/Q35540013

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

PTEN protein loss and clinical ...... ated with abiraterone acetate.

@ast

PTEN protein loss and clinical ...... ated with abiraterone acetate.

@en

type

label

PTEN protein loss and clinical ...... ated with abiraterone acetate.

@ast

PTEN protein loss and clinical ...... ated with abiraterone acetate.

@en

prefLabel

PTEN protein loss and clinical ...... ated with abiraterone acetate.

@ast

PTEN protein loss and clinical ...... ated with abiraterone acetate.

@en

P1433

Q35540013-24F1E0C8-2F89-4912-A16C-BB0BA81AB0C6

P1476

Q35540013-1E36AF4A-02AF-421E-856B-2F219F9562FF

P2093

Q35540013-16431BCA-C57A-4280-9AB1-95ED4FCF5954

Q35540013-2CFE4187-3D0A-482E-81B0-CE5707227A3C

Q35540013-3985484C-41B6-4281-A6D3-513A073FE4A2

Q35540013-41531521-BEF9-4932-910F-79FAB18BE14F

Q35540013-4C4EC74F-7E9A-46E8-A520-0C3DA9D1DA6E

Q35540013-572874CB-ED2E-4751-914E-5CB6A872FAC3

Q35540013-71233F2D-EA78-4BDB-A5E9-7131AF305F32

Q35540013-75CC5671-539F-42F5-BD7C-DFF18F21745A

Q35540013-7803BEB2-576F-40E9-A77D-E9B9AFA0C35F

Q35540013-7DA62DEA-54B0-441C-978E-772D74029AEC

P2860

Q35540013-00614C40-7B33-4B12-9983-2BBF56931750

Q35540013-052CD813-2BB9-4C55-BD00-C329338ACD45

Q35540013-12FD284D-7094-45CB-B8F2-9B0551C6D943

Q35540013-3A21A4BB-04CA-4321-93E0-F6D8EF4B4B67

Q35540013-3B90D9F5-AACF-42BF-893D-4D7DD1F3F02D

Q35540013-401CD26E-24C8-4A7B-A73D-885B5C15B782

Q35540013-4917FADC-563E-4296-A930-E5A327A0DFF4

Q35540013-4A298B8C-4A59-405C-B328-74914068EAED

Q35540013-6549F36C-74B3-4FAC-ACB2-048481EF12FE

Q35540013-65DEAAB7-9E55-4037-9BFE-9C07505EC4AA

P304

Q35540013-934D8731-4A16-49E9-BA99-C0FF73F91E10

P31

Q35540013-1C4C6C35-BF7C-45D9-B31C-C25BA5B98577

P356

Q35540013-25E5948A-A2B1-4E12-9C26-950473BB7140

P407

Q35540013-629C129C-2797-4BC8-AACD-774BFC15FF7E

P433

Q35540013-B8EE1F65-18FC-45EB-9844-1AB3FE0FD1FF

P478

Q35540013-3707B126-43BB-4966-BA0B-9855E03CA62F

P50

Q35540013-77C38393-EFF8-4ABF-BED1-E38CB9B01E12

Q35540013-7DB9E68C-6D92-4E1E-B87B-E261B869F044

Q35540013-876506B6-9F19-42C5-8E48-64FAB9920C0F

Q35540013-BC332E4B-F2D4-4ABD-B988-B123F5FB6B3C

Q35540013-F5E7EC9B-D838-4492-97B5-DD61C5290D9A

P577

Q35540013-80521D14-2983-42A6-A1DA-A3CA340CBF89

P5875

Q35540013-7BFA2E6E-F0B0-4AD0-950D-CE114D078533

P698

Q35540013-A99EF8D1-BA7F-4870-AE9B-AAE8269AE986

P932

Q35540013-EF930B99-164D-40D4-A6DD-81C9982D4AC8

P356

J.EURURO.2014.10.027

P1433

European Urology

P1476

PTEN protein loss and clinical ...... eated with abiraterone acetate

@en

P2093

Alison Reid

http://www.w3.org/2001/XMLSchema#string

Aurelius Omlin

http://www.w3.org/2001/XMLSchema#string

Carmel Pezaro

http://www.w3.org/2001/XMLSchema#string

Chris Parker

http://www.w3.org/2001/XMLSchema#string

Daniel Nava Rodrigues

http://www.w3.org/2001/XMLSchema#string

David Dearnaley

http://www.w3.org/2001/XMLSchema#string

Diletta Bianchini

http://www.w3.org/2001/XMLSchema#string

Emily Grist

http://www.w3.org/2001/XMLSchema#string

Ines Figueiredo

http://www.w3.org/2001/XMLSchema#string

Joaquin Mateo

http://www.w3.org/2001/XMLSchema#string

P2860

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

Integrative genomic profiling of human prostate cancer

Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis.

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer

New strategies in prostate cancer: translating genomics into the clinic

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

P304

795-802

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2014.10.027

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

Gerhardt Attard

Pasquale Rescigno

Amelia Altavilla

P577

2014-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269171317

http://www.w3.org/2001/XMLSchema#string

P698

25454616

http://www.w3.org/2001/XMLSchema#string

P932

4410287

http://www.w3.org/2001/XMLSchema#string